Liver Diseases  >>  trebananib (AMG 386)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
trebananib (AMG 386) / Amgen
NCT00872014 / 2008-006212-38: A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer

Checkmark ASCO-GI 2014
Jan 2014 - Jan 2014: ASCO-GI 2014
Completed
2
60
US, Europe, RoW
AMG 386, Sorafenib
Amgen
Advanced Hepatocellular Carcinoma, Inoperable Hepatocellular Carcinoma
10/11
06/15

Download Options